Myrobalan News
Myrobalan Therapeutics Awarded a Grant from the National Multiple Sclerosis Society to Advance Development of MRO-002 in Multiple Sclerosis
Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer
Myrobalan Therapeutics Strengthens Board of Directors with Appointment of Emma Reeve
Myrobalan Presents GPR17 Antagonist Preclinical Data at ECTRIMS 2024
Myrobalan Therapeutics Names Grant Bogle to Board of Directors
Co-Founder, Professor Guoping Feng (MIT/Broad) Inducted into the National Academy of Sciences
Myrobalan Therapeutics Receives a Grant from the ALS Association to Advance its CSF1R Inhibitor Program
Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential
